Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4229055 | 0.98 | MEN1 (0.47) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL5192232 | 0.87 | CYP2D6 (0.59) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL4188000 | 0.87 | CYP2D6 (0.59) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL4172951 | 0.87 | CYP2D6 (0.59) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL13400663 | 0.85 | LPAR1 (0.42) | CYP2D6MEN1KMT2APARP10ALDH1A1 | |
| SCHEMBL13877387 | 0.81 | HIF1A (0.47) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| Hydrochloric Acid SCHEMBL4225657 | 0.79 | MEN1 (0.46) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL10636549 | 0.79 | CA2 (0.64) | CYP2D6MEN1KMT2APARP10ALDH1A1 | |
| SCHEMBL31570095 | 0.78 | ALDH1A1 (0.66) | MEN1KMT2APARP10ALDH1A1CA12 | |
| SCHEMBL19612492 | 0.77 | CA12 (0.56) | CYP2D6MEN1MAPK1KMT2APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | CYP2D6 50/4885ADRA2A 195/4885ADRA1A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.